A new study in mice adds to the evidence suggesting that the immune system not only attacks invading pathogens but can also influence mood.

Over the past few years, scientists have discovered some intriguing links between immunity and the mind.

One of the immune signaling molecules, or cytokines, that mediates these links is called interleukin-17a (IL-17a).

IL-17a plays a role in psoriasis, which is an autoimmune skin condition, but it may also contribute to the depression that many people experience. Indeed, a study involving a mouse model of psoriasis found that IL-17a caused depression-like symptoms.

In humans, researchers have also linked the molecule to treatment resistant depression.

Research in mice has even implicated IL-17a in the development of autism.

The brain and the body are not as separate as people think, says Prof. Jonathan Kipnis, a neuroscientist at the Washington University School of Medicine in St Louis, MO.

While working at the University of Virginia School of Medicine in Charlottesville, Prof. Kipnis and colleagues found that IL-17a causes anxiety-like behavior in mice.

We are now looking into whether too much or too little of IL-17a could be linked to anxiety in people, says Prof. Kipnis.

The scientists have published the results of their mouse study in the journal Nature Immunology. Kalil Alves de Lima, a postdoctoral researcher who is also now at the University of Washington, led the research.

Immune cells called gamma-delta T cells produce IL-17a. The cells are present in the meninges, which are the membranes surrounding the brain and spinal cord.

To determine what effect IL-17a might have on behavior, the scientists studied mice whose gamma-delta T cells did not produce any IL-17a and mice who lacked the cells completely.

They put the mice through standard tests of memory, social behavior, foraging, and anxiety. The mice performed just as well as normal mice on all tests apart from two that measure anxiety levels.

In those tests, the mice who lacked gamma-delta T cells or did not produce any IL-17a were more likely to explore open areas. In the wild, this kind of behavior would put them at greater risk of being eaten by predators.

The researchers interpreted this as a sign of reduced anxiety in animals without IL-17a signaling in their central nervous system.

Next, the scientists investigated how the signal affects neurons in their brains. They found receptors for IL-17a on a type of stimulatory nerve cell called a glutamatergic neuron.

When they genetically manipulated the neurons to prevent them from making these receptors, the mice exhibited less anxiety-like behavior.

Previous animal research has revealed a multitude of possible links between bacteria living in the gut and behavior, including anxiety-like behaviors.

This connection is known as the gut-brain axis, and scientists have proposed the immune system as one possible way that messages pass between them.

To investigate the role of IL-17a in the gut-brain axis, Alves de Lima and colleagues injected the mice with lipopolysaccharide. This is a toxin that bacteria produce. It provokes a strong immune reaction.

In response to the injection, gamma-delta T cells in the meninges surrounding the animals brains produced more IL-17a.

In another experiment, when the researchers treated the mice with antibiotics to kill the bacteria in their guts, the animals produced less IL-17a.

Together, the results of these experiments suggest that the immune system has evolved not only to fight infection but also to adjust behavior to keep animals safe while they are in a weakened state.

Selecting special molecules to protect us immunologically and behaviorally at the same time is a smart way to protect against infection. This is a good example of how cytokines, which basically evolved to fight against pathogens, also are acting on the brain and modulating behavior.

Kalil Alves de Lima

The team is now investigating how gamma-delta T cells in the meninges surrounding the brain can detect the presence of bacteria elsewhere in the body.

The researchers are also looking into exactly how IL-17a signaling in the brain changes behavior.

In their paper, they conclude:

Our findings provide new insights into the neuroimmune interactions at the meningealbrain interface and support further research into new therapies for neuropsychiatric conditions.

Although the physiology of mice and humans is very similar, scientists need to carry out much more research to explore the possible links between the human immune system and mood.

Read the original:

Immune system may trigger anxiety in response to infection - Medical News Today

It may be possible to modify some lifestyle and environmental factors to reduce the risk of patients transitioning from psoriasis to psoriatic arthritis.

Psoriatic arthritis (PsA) occurs in approximately one-third of patients with psoriasis, but it may be possible to modify some lifestyle and environmental factors to reduce the risk of patients transitioning from psoriasis to PsA, according to research published in Journal of the American Academy of Dermatology.

PsA causes pain, swelling, and joint stiffness, and it is associated with impaired quality of life, a greater risk of comorbidities, and higher health care expenditures. The underlying events that cause the transition to PsA are not well understood, but current thought is that heredity and the environment both play a role.

determining the modifiable factors associated with transition to PsA among patients with psoriasis may provide a unique opportunity for early prevention and deepen our understanding of the etiology of PsA as well, the authors explained.

The researchers conducted a systematic search of PubMed, EMBASE, and Cochrane Library for observational studies reporting lifestyle or environmental factors for PsA onset in patients with psoriasis. The included 16 studies in their analysis. The studies originated from the United Kingdom (n = 6), Canada (n = 4), the United States (n = 4), Japan (n = 1), and Singapore (n = 1) and they included 322,967 patients.

Nine of the studies assessed the association between smoking and PsA. There were 8 studies on alcohol consumption in patients with psoriasis. Eight studies investigated the risk of PsA onset by body mass index (BMI). A total of 5 studies analyzed physical trauma and the presence of PsA.

The meta-analysis of BMI found a dose-dependent increase in the risk of developing PsA for patients with psoriasis. The risk increased 75% for patients with obesity. Despite the potential causal association between PsA and obesity, the underlining mechanisms are not completely understood, the authors wrote. They conjectured that chronic low-grade inflammation status in patients with obesity represents an increase in inflammatory cytokines and an alternation in adipokines, which might lead to the development of PsA in predisposed individuals.

The association between smoking and risk of PsA among patients with psoriaris remains unclear due to severely conflicting findings. One case-control study found a protective relationship, but more recently updated research using the same database showed smoking status was unrelated to PsA risk. However, another study using a large cohort of women found an elevated risk. The authors determined there was no association between smoking status (whether patients had ever smoked, currently smoked, or were past smokers) and the risk of developing PsA.

The authors did note a significant increase in the risk of developing PsA in patients with psoriasis who had had experienced traumatic injury. Individuals with psoriasis who are exposed to physical trauma, such as fracture, may transition from psoriasis to PsA.

The researchers did note their findings require caution since they were interpreting evidence from observational studies, which can be more biased than randomized controlled trials. In addition, not all the studies adjusted enough for potential confounders.

The results of the study highlight a need to strengthen public health to promote awareness and endeavor to reduce the risk of transition to PsA in psoriasis patients, and furthermore deepen our understanding of the etiology of PsA, the authors concluded.

Reference

Xie W, Huang H, Deng X, Gao D, Zhang Z. Modifiable lifestyle and environmental factors associated with onset of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol. Published online August 19, 2020. doi:10.1016/j.jaad.2020.08.060

Go here to read the rest:

Modifiable Risk Factors Associated With Transition From Psoriasis to Psoriatic Arthritis - AJMC.com Managed Markets Network

Qiaolin Wang,1 3 Yan Luo,1 3 Chengzhi Lv,4 Xuanwei Zheng,1 3 Wu Zhu,1 3 Xiang Chen,1 3 Minxue Shen,1 3,5 Yehong Kuang1 3

1Department of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, Peoples Republic of China; 2National Clinical Research Center for Geriatric Disorders (Xiangya Hospital), Changsha 410008, Peoples Republic of China; 3Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis (Xiangya Hospital), Changsha 410008, Peoples Republic of China; 4Department of Psoriasis, Dalian Dermatosis Hospital, Dalian, Liaoning 116021, Peoples Republic of China; 5Department of Social Medicine and Health Management, Xiangya School of Public Health, Central South University, Changsha 410078, Peoples Republic of China

Correspondence: Yehong Kuang; Minxue ShenXiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan, Peoples Republic of ChinaEmail yh_927@126.com; shenmx1988@csu.edu.cn

Purpose: The COVID-19 epidemic has caused difficulties in continuous treatment for patients with chronic diseases and resulted in nonadherence to treatment and adverse health outcomes. This study aimed to investigate the associations of nonadherence to treatment with patient-reported outcomes of psoriasis during the COVID-2019 epidemic.Methods: A cross-sectional study among Chinese patients with psoriasis was conducted through a web-based questionnaire survey during 25 Feb 2020 and 6 Mar 2020. Demographic and clinical data, nonadherence to treatment, and patient-reported outcomes were collected. The outcomes included deterioration of the disease condition, perceived stress, and symptoms of anxiety and depression. Logistic regression was used to investigate the associations.Results: A total of 926 questionnaires were collected. A total of 634 (68.5%) reported nonadherence to treatment, and worse adherence was found among patients receiving systemic treatment (adjusted odds ratio [AOR]: 2.67; 95% CI: 1.40 5.10) and topical treatment (AOR: 4.51; 95% CI: 2.66 7.65) compared to biological treatment. Nonadherence to treatment (less than two weeks and more than two weeks) wassignificantly associated with deterioration of psoriasis (aOR: 2.83 to 5.25), perceived stress (AOR: 1.86 to 1.57), and symptoms of anxiety (AOR: 1.42 to 1.57) and depression (AORs: 1.78). Subgroup analysis by treatment showed consistent results in general.Conclusion: Nonadherence to treatment was associated with the aggravation of psoriasis conditions, perceived stress, and symptoms of anxiety and depression.

Keywords: psoriasis, coronavirus disease 2019, patient-reported outcome, treatment adherence

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read the original post:

Nonadherence to Treatment and Patient-Reported Outcomes of Psoriasis D | PPA - Dove Medical Press

DUBLIN--(BUSINESS WIRE)--The "Global Psoriasis Treatment Market - Analysis by Type, by Treatment Method, by Region, by Country (2020 Edition): Market Insights and Outlook Post Covid-19 Pandemic (2020-2025)" report has been added to ResearchAndMarkets.com's offering.

Global Psoriasis Treatment Market was valued at USD 16.7 billion in the year 2019.

Rising prevalence of psoriasis affected people, rise in research and investments in developing biological treatment, rise in awareness of psoriasis coupled with the rising demand for healthcare products are the major factors impelling the market growth. Major growth in the forecast period is likely to be demonstrated from the various drugs that are in the clinical stages and would be available commercially in the next 3-5 years. This includes among others, the most promising ARQ-154 Foam for scalp psoriasis, from the US biotechnology company, Arcutis, which has the potential to become a billion-dollar opportunity for the treatment of psoriasis.

Genetic disposition, rising geriatric population and increasing government initiatives creating psoriasis awareness have been anticipated to infuse growth in the market for Psoriasis during the forecasting period of 2020-2025. Factors such as rising geriatric population, practice of unhealthy lifestyle such as heavy consumption of alcohol, smoking tobacco, enaction of immunity framework, stress and sunburn are crucial factors are supposed to trigger Psoriasis and Psoriasis arthritis that is consequently accelerating the demand for Psoriasis treatment and medication.

The growth of the market is hampered in 2020 due to the occurrence of coronavirus pandemic in which all worldwide business activities are put at hold for the first few months of the year. IPC recommended physicians to discontinue or postpone use of immunosuppressant medications for the psoriasis patients, which is negatively affecting the Psoriasis drugs market growth. However, as per National Psoriasis Foundation the Medicare extended its inclusion of telehealth administrations in amid COVID-19 pandemic due to which the treatment has been resumed and the drug market has been supported in few first few months of 2020 that are anticipated to recover and accelerate the demand for the treatment in the coming years.

Under the Type Segment, Plaque Psoriasis is the most common type of psoriasis and dominates the overall psoriasis market. The developing number of advanced medicines for the treatment of plaque psoriasis by the key players is augmenting the demand for enhanced medication.

The continual research and development in a number of biologics and biosimilars by the drug developing companies are expected to propel market demand of biologics treatment method for psoriasis. Among the regions, North America is followed by and Europe and Asia Pacific. Asia Pacific region is the most attractive region for the growth of Psoriasis treatment owing large targeted population base coupled with increasing healthcare spending, prevalence of psoriasis or psoriatic arthritis patients, rise in government contribution and awareness programs.

Scope of the Report

Key Topics Covered

1. Report Scope and Methodology

1.1 Scope of the Report

1.2 Research Methodology

1.3 Executive Summary

2. Strategic Recommendations

3. Global Psoriasis Treatment Market: Product Outlook

4. Global Psoriasis Treatment Market: Sizing, Growth and Forecast

4.1 Market Size, By Value, Year 2015-2025

5. Global Psoriasis Treatment Market Segmentation By Type (By Value)

5.1 Competitive Scenario of Global Psoriasis Market - By Type (2019 & 2025)

5.2 Plaque Psoriasis- Market Size and Forecast (2020-2025)

5.3 Inverse Psoriasis- Market Size and Forecast (2020-2025)

5.4 Guttate Psoriasis- Market Size and Forecast (2020-2025)

5.5 Pustular Psoriasis- Market Size and Forecast (2020-2025)

5.6 Erythrodermic Psoriasis- Market Size and Forecast (2020-2025)

6. Global Psoriasis Market Segmentation By Treatment Method (By Value)

6.1 Competitive Scenario of Global Psoriasis - By Treatment Method (2019 & 2025)

6.2 Biologics - Market Size and Forecast (2020-2025)

6.3 Systemic Treatment- Market Size and Forecast (2020-2025)

6.4 Topical Treatment- Market Size and Forecast (2020-2025)

6.5 Others - Market Size and Forecast (2020-2025)

7. Global Psoriasis Treatment Market: Regional Analysis

7.1 Competitive Scenario of Global Psoriasis Market : By Region (2019 & 2025)

8. North America Psoriasis Market: Segmentation By Type, By Treatment Method (2020-2025)

8.1 North America Psoriasis Treatment Market: Size and Forecast (2020-2025)

8.2 North America Prominent Companies in Psoriasis Market

8.3 Market Segmentation By Type (Plaque Psoriasis, Inverse Psoriasis, Guttate Psoriasis, Pustular Psoriasis- & Erythrodermic Psoriasis)

8.4 Market Segmentation By Treatment Method (Biologics, Systemic Treatment, Topical Treatment & Others)

8.5 North America Psoriasis Market: Country Analysis

8.6 Market Opportunity Chart of North America Psoriasis Market - By Country, By Value (Year-2025)

8.7 Competitive Scenario of North America Psoriasis Market: By Country (2019 & 2025)

8.8 United States Psoriasis Market: Size and Forecast (2020-2025)

8.9 United States Psoriasis Market Segmentation By Type, By Treatment Method (2020-2025)

8.10 Canada Psoriasis Market: Size and Forecast (2020-2025)

8.11 Canada Psoriasis Market Segmentation By Type, By Treatment Method (2020-2025)

9. Europe Psoriasis Market: Segmentation By Type, By Treatment Method (2020-2025)

10. Asia Pacific Psoriasis Market: Segmentation By Type, By Treatment Method (2020-2025)

11. Global Psoriasis Treatment Market Dynamics

11.1 Global Psoriasis Market Drivers

11.2 Global Psoriasis Market Restraints

11.3 Global Psoriasis Market Trends

12. Market Attractiveness

12.1.1 Market Attractiveness Chart of Global Psoriasis Treatment Market - By Type (Year 2025)

12.1.2 Market Attractiveness Chart of Global Psoriasis Market - By Treatment Method (Year 2025)

12.1.3 Market Attractiveness Chart of Global Psoriasis Treatment Market - By Region, By Value, (Year-2025)

13. Competitive Landscape

13.1 Psoriasis Pipeline Analysis

13.2 Market Share Analysis

14. Company Profiles (Business Description, Financial Analysis, Business Strategy)

14.1 UCB

14.2 Sun Pharmaceutical Industries Ltd.

14.3 Boehringer Ingelheim

14.4 Almirall

14.5 Bausch Health

14.6 Abbvie Inc.

14.7 Eli Lilly and Company

14.8 Pfizer Inc.

14.9 Amgen Inc.

14.10 Johnson & Johnson

For more information about this report visit https://www.researchandmarkets.com/r/lfp8z9

Read the original here:

Global Psoriasis Treatment Market by Type, Treatment Method, Region and Country (2020 Edition): Market Insights and Outlook Post COVID-19 Pandemic...

Background:The comparative efficacy and safety of small molecule and biological agents in the treatment of psoriatic arthritis (PsA) remain unknown.

Objectives:To compare the efficacy and safety of 14 small molecule and biological agents by network meta-analysis (NMA).

Methods:Relevant randomized controlled trials involving biological treatments for PsA were identified by searching PubMed, Cochrane Library, EMBASE, Web of Science, and Clinicaltrials.gov and by manual retrieval, up to June 2018. NMA was conducted with Stata 14.0 based on the frequentist method. Effect measures were odds ratios (ORs) with 95% confidence intervals (CIs). Intervention efficacy and safety were ranked according to the surface under the cumulative ranking curve (SUCRA).

Results:A total of 30 studies involving 10,191 adult subjects were included. According to NMA, 20% improvement in modifed American College of Rheumatology response criteria (ACR20) response, Psoriasis Area and Severity Index 75 (PASI75) response, and serious adverse events rate (SAEs) were observed. In direct comparisons, most of the biologics performed better than placebo in terms of ACR20 response rate and PASI75 response rate. Additionally, all medicines were comparable to placebo in terms of SAEs except secukinumab. In terms of mixed comparisons, with regard to the ACR20 response, etanercept (ETN) and infliximab (IFX) were more effective than golimumab (GOL), with ORs of 3.33 (95% CI: 1.17-9.48) and 1.24 (95% CI: 0.61-2.52), respectively. For PASI75 response, IFX was superior to certolizumab pegol (OR = 10.08, 95% CI: 1.54-75.48). In addition, these medicines were comparable to each other in terms of SAEs. ETN and IFX were shown to have the most favorable SUCRA for achieving improved ACR20 and PASI75 responses, respectively, while ABT-122 exhibited the best safety according to the SUCRA for SAEs. Considering both the efficacy (ACR20, PASI75) and safety (SAEs), GOL, ETN, and IFX are the top 3 treatments.

Conclusions and implications:Direct and indirect comparisons and integrated results suggested that the 3 anti- tumor necrosis factor - biologics (GOL, ETN, and IFX) can be considered the best treatments for PsA after comprehensive consideration of efficacy and safety.

See the original post:

Fourteen small molecule and biological agents for psoriatic arthritis: A network meta-analysis of randomized controlled trials - DocWire News

Psoriasis is a relatively common skin disorder where skin cells multiply almost 10 times faster than normal. This results in the build-up of bumpy red patches covered with white scales. Though they can grow anywhere, such patches are usually seen on the scalp, elbows, knees, and lower back. In severe cases, it can cover almost the entire body. It is not a contagious condition. It can cause severe itching, bleeding and cracking of skin. Sometimes, it also affects the fingernails and toenails, including discoloration and pitting of the nails. Psoriatic arthritis is also common among people with this condition. It causes pain and swelling in the joints. This is usually a hereditary condition. But stress, allergies and some medications can also trigger this condition. Also Read - Ayurvedic treatment for Psoriasis: Can Panchakarma therapy really help?

Treatment for this condition includes topical application of steroid creams, moisturizers, creams and ointments. Retinoid creams also help deal with the symptoms as can light therapy. This is a log-lasting condition interspersed with flare-ups and long periods of remission. Other than Allopathy, sometimes, alternative healing therapies may also help you deal with the symptoms. Ayurveda, the ancient healing therapy from India, can help you here. Also Read - Turmeric, apple cider vinegar and other home remedies for psoriasis

This healing therapy, which was developed more than 3,000 years ago, uses a combination of diet, exercise, lifestyle changes and some Ayurvedic medicines. Though some experts say that there is no proof that Ayurveda can help, advocates say that it really does help in the treatment of psoriasis. It goes without saying that some Ayurvedic practices, like eating veggies and drinking plenty of water, are healthy for everyone including psoriasis patients. But practices like bloodletting may be unsafe in the wrong hands. So, you must always go to a certified Ayurveda doctor for treatment. Also Read - 5 effective home remedies to treat psoriasis

Ayurveda believes that everyone is made up of five basic elements: Air, earth, fire, ether and water. Together, these elements form life forces called doshas. The three doshas are vata, which is ether and air, pitta, which is fire and water, and Kapha, which is water and earth. According to this healing therapy, psoriasis results from unbalanced vata and kapha doshas. Toxins, stress, and certain foods, like yogurt, seafood, and salty food, can also cause this condition.

In Ayurveda, your treatment will depend on your symptoms and lifestyle. It may include diet changes, specific herbs, massage with specially formulated oils, enemas or laxatives and controlled vomiting. Sometimes, treatment may also involve blood cleansing using herbs or bloodletting, which involves draining blood from your body.

You ma be asked to drink lots of water and eat green, leafy vegetables. Turmeric, which reduces inflammation and has antioxidant properties is an important of treatment here. You may also be asked to apply a paste made from a botanical powder made from the andira araroba tree, mixed with vinegar or lemon juice to psoriasis patches. Olive oil is also used for topical application as is cayenne pepper and aloe vera. Moreover, your therapist may ask you to avoid foods and drinks like alcohol, red meat, spicy food, junk food and acidic foods.

Published : August 8, 2020 6:12 pm | Updated:August 8, 2020 6:20 pm

Continue reading here:

Psoriasis is a debilitating condition: Try Ayurveda to deal with symptoms - TheHealthSite

Alwan, W., and F.O. Nestle. "Pathogenesis and Treatment of Psoriasis: Exploiting Pathophysiological Pathways for Precision Medicine." Clin Exp Rheumatol 33 (Suppl. 93): S2-S6.

Arndt, Kenneth A., eds., et al. "Topical Therapies for Psoriasis." Seminars in Cutaneous Medicine and Surgery 35.2S Mar. 2016: S35-S46.

Benhadou, Fairda, Dillon Mintoff, and Vronique del Marmol. "Psoriasis: Keratinocytes or Immune Cells -- Which Is the Trigger?" Dermatology Dec. 19, 2018.

Conrad, Curdin, Michel Gilliet. "Psoriasis: From Pathogenesis to Targeted Therapies." Clinical Reviews in Allergy & Immunology Jan. 18, 2015.

Dowlatshahi, E.A., E.A.M van der Voort, L.R. Arends, and T. Nijsten. "Markers of Systemic Inflammation in Psoriasis: A Systematic Review and Meta-Analysis." British Journal of Dermatology 169.2 Aug. 2013: 266-282.

Georgescu, Simona-Roxana, et al. "Advances in Understanding the Immunological Pathways in Psoriasis." International Journal of Molecular Sciences 20.739 Feb. 10, 2019: 2-17.

Greb, Jacqueline E., et al. "Psoriasis." Nature Reviews Disease Primers 2 (2016): 1-17.

Kaushik, Shivani B., and Mark G. Lebwohl. "Review of Safety and Efficacy of Approved Systemic Psoriasis Therapies." International Journal of Dermatology 2018.

National Psoriasis Foundation. "Systemic Treatments: Biologics and Oral Treatments." 1-25.

Ogawa, Eisaku, Yuki Sato, Akane Minagawa, and Ryuhei Okuyama. "Pathogenesis of Psoriasis and Development of Treatment." The Journal of Dermatology 2017: 1-9.

Stiff, Katherine M., Katelyn R. Glines, Caroline L. Porter, Abigail Cline & StevenR. Feldman. "Current pharmacological treatment guidelines for psoriasis and psoriaticarthritis." Expert Review of Clinical Pharmacology (2018).

Villaseor-Park, Jennifer, David Wheeler, and Lisa Grandinetti. "Psoriasis: Evolving Treatment for a Complex Disease." Cleveland Clinic Journal of Medicine 79.6 June 2012: 413-423.

Woo, Yu Ri, Dae Ho Cho, and Hyun Jeong Park. "Molecular Mechanisms and Management of a Cutaneous Inflammatory Disorder: Psoriasis." International Journal of Molecular Sciences 18 Dec. 11, 2017: 1-26.

Read this article:

Psoriasis: Types, Pictures, Causes, Symptoms, Treatments ...

Cyndi Lauper was diagnosed with psoriasis, an auto-immune chronic disorder, in 2010. The condition leads to red and raised patches lined by silvery scales on the skin and for Lauper, it started with her scalp which she at first thought must be because of bugs. "I had this kind of buildup on my scalp, which, because my son played hockey at the time, I thought Oh, it might be bugs (from the hockey players). Id never had bugs. Then I went to the doctor and he said, 'No, no, no, thats plaque psoriasis,'" she said in an interview with Health.

She always had good skin while growing up but after her diagnosis, she started to lose hope of feeling good in her skin ever again. As a singer who is constantly on the go, the disease pulled her down really hard. "Youre tired. Its an inflammatory disease so it kind of zaps your strength. And trying to sing, work out, and have all this (clothing) on, and then taking it off, your skin comes with it. Its awful. Emotionally, honestly, at the height of being that sick, you feel very much alone." After trying out cortisone creams, she realized that the side-effects of it were too much to deal with and that is when she turned to traditional medicine.

"Now I can get back to the things I like to do, like singing and going on tour. After I started the medicine, psoriasis started to go away, and I couldnt even believe it. I was always on eggshells. I still lather up with cream and am nervous because I dont want to go back to that," she said. Lauper also advocates seeking medical assistance and self-care for people affected by this condition. She spoke about the importance of the same elaborately in an awareness video by the National Psoriasis Foundation in 2015. In the video, she says that she tried every method in the book including the time she slept in a rubber suit with cream on for three nights straight, a measure taken upon a doctor's advice that happened to eventually work for her.

The reason why she lends her voice to Psoriasis awareness is that she believes the condition "is one of those things that no one wants to talk about, which makes it something I want to talk about". As a word of advice for people with psoriasis, she said, "Its not just a rash. Dont let it go. Get information. Knowledge is power." She also advocates taking measures for taking steps to keep one's mental health in check as the disease affects more than just the skin. "Youre hurting inside because you feel powerless and information is power. Help yourself. Dont just sit in the dark," she said.

August is Psoriasis Awareness Month and it brings an opportunity for survivors and activists to share tips and raise awareness about the genetic disease. In this column, we highlight the struggles of celebrities and talk about preventative and cure measures.

Here is the original post:

Psoriasis Awareness Month: Cyndi Lauper slept in a rubber suit for three nights straight to beat the disease - MEAWW

(MENAFN - GetNews) Psoriasis Treatment Market Size, Trends and Growth Analysis by Drug Class [Tumour Necrosis Factor Inhibitors (Adalimumab, Infliximab and Etanercept), Interleukin-Inhibitors (Ustekinumab, Secukinumab, Ixekizumab and Brodalumab), Vitamin D Analogues (Calcitriol, Calcipotriol and Tacalcitol)], Treatment Type and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2025

Psoriasis Treatment Market Overview

The Global Psoriasis Treatment Market is growing rapidly. The market growth attributes o the availability of several breakthrough therapeutics and drugs to treat symptoms of psoriasis. Over recent years, technological advancements have brought notable innovations in psoriasis treatments, offering phenomenal relief and benefitting results. These improvements increase the psoriasis market size, proving to be a boon to the patients by improving their quality of life.

According to Market Research Future (MRFR), the global psoriasis treatment market size is expected to reach USD 13.1 Billion by 2025, growing at 7.3% CAGR during the review period (2019-2025). Rising prevalence rate of psoriasis is one of the prime factors propelling market growth. Besides, the availability of breakthrough psoriasis drugs on the market fosters the growth of the market. Valuation of the market is anticipated to progress massively in the near future, witnessing the emergence of many new treatments.

Request Free Sample Copy at: [To enable links contact MENAFN]

The increasing demand for effective psoriasis treatments pushes the market growth of the market to the ascended level. Conversely, the lack of awareness and unmet medical needs are the major factors expected to obstruct the market growth. Nevertheless, growing technology upgrades would support market growth throughout the assessment period. Furthermore, the increased funding for research and development from the public and private sectors would provide impetus to the market growth.

Psoriasis Treatment Market Segmentations

By Drug Class : Tumour Necrosis Factor Inhibitors (Adalimumab, Infliximab, Etanercept), K.in-Inhibitors (Ustekinumab, K.inumab, Ixekizumab, Brodalumab), Vitamin D Analogues (Calcitriol, Calcipotriol, Tacalcitol), and others.

By Treatment Type: Topicals (Over the Counter (OTC) Topicals, Topical Non-Steroids, Topical Steroids), Systemic (Retinoid, Cyclosporine, Methotrexate), Biologics (Tumour Necrosis Factor Alpha (TNF-a) Inhibitors, K.in 12 and 23 (IL-12/23) Inhibitors, K.in 17 (IL-17) Inhibitor, T Cell Inhibitor), and others.

Psoriasis Treatment Market Regional Outlook

North America dominates the global psoriasis treatments market. The largest market share attributes to the rising prevalence of psoriasis among children as well as adults. Besides, the strong presence of notable players and well-established treatment centers in the region impact the market growth positively. Moreover, high per capita healthcare expenditures and early adoption of new technology in the region substantiate the regional market growth. High cases of psoriasis in the US and Canada is expected to drive the market growth. The North American psoriasis treatments market is projected to retain its dominance over the global market throughout the forecast period.

Europe stands second in the global psoriasis treatment market. Positive amendments in the reimbursement policies drive the market. Furthermore, increasing expenses in research by healthcare bodies fuel the growth of the market in this region. Also, rising healthcare expenses allow the market to showcase a considerable amount of growth.

Additionally, the presence of a well-established healthcare system and key industry players, alongside technology upgrades in medical devices and therapeutics, drives the regional market growth. The European psoriasis treatments market is expected to create a substantial revenue pocket over the assessment period.

The Asia Pacific psoriasis treatments market is growing rapidly. Factors such as the increasing demand for spine surgeries and increasing government initiatives for healthcare reforms boost the regional market growth. Besides, a large patient pool and expansion of healthcare in the region drive the growth of the market. Furthermore, growing per capita healthcare expenditures and developing economies provide an impetus to the regional market. The APAC psoriasis treatments market is projected to have a steady growth rate during the forecast period.

Psoriasis Treatment Market Competitive Analysis

Highly competitive, the global psoriasis treatment appears fragmented due to the presence of several well-established industry players. These players adopt strategic initiatives such as mergers & acquisitions, collaborations, expansion, and technology launch to gain a larger competitive advantage. Psoriasis pharmaceutical companies invest substantially in R & D and clinical trials to develop effective drugs and therapeutics.

Psoriasis pharmaceutical companies collaborate with a number of partners from academia to the biotech industry who contribute specialized knowledge and cutting-edge technologies to accelerate pharmaceutical innovations and gain a better understanding of the condition. These collaborations form one of the pillars of the company's innovation strategy. Through partnerships, companies can leverage scientific know-how and use it for innovative medicines. Partnerships can leverage innovative impulses that advance medicine and benefit patients and partners.

Major Players:

Players leading the psoriasis treatment market include UCB (Belgium), Novartis International AG (Switzerland), AstraZeneca (UK), Johnson & Johnson (US), Celgene Corporation (US), Pfizer Inc (US), AbbVie (US), Merck and Co. Inc (US), Eli Lilly and Company (US), and Amgen (US), among others.

Browse Detailed TOC with COVID-19 Impact Analysis at: [To enable links contact MENAFN]

Industry/Innovation/ Related News:

A team of researchers at John A. Paulson School of Engineering and Applied Sciences (SEAS) and Harvard's Wyss Institute for Biologically Inspired Engineering published their study, stating that siRNA-based treatment can reduce psoriasis symptoms significantly.

Scientists circumvented limitations by using an ionic liquid (IL) combination to deliver a small interfering RNA (siRNA)-based treatment successfully to the skin in a mouse model of psoriasis, significantly reducing levels of inflammatory cytokines and symptoms of psoriasis without systemic side effects.

Browse More Healthcare Related Research Report at:

Contact Lenses Market Research Report - Global Forecast till 2025 [To enable links contact MENAFN]

NOTE: Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Media Contact Company Name: Market Research Future Contact Person: Abhishek Sawant Email: Send Email Phone: +1 646 845 9312 Address: Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar City: Pune State: Maharashtra Country: India Website: [To enable links contact MENAFN]

Originally posted here:

Psoriasis Treatment Market Size to Witness a CAGR Exceeding 7.3% By 2025 | Growth Insights, COVID-19 Impact, Share Estimation and Future Trends -...

WESTLAKE VILLAGE, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, announced today that The Journal of Drugs in Dermatology has published positive results from a Phase 1/2a trial of its investigational drug topical roflumilast cream for the treatment of chronic plaque psoriasis. The article has been published in the August 2020 issue of the journal. These results demonstrate that ARQ-151 (roflumilast cream) was safe and highly effective at doses of 0.5% and 0.15%, and represents a potential novel once-daily topical therapy for the treatment of chronic plaque psoriasis.

Psoriasis imposes a high burden for patients, and current standards of care to treat this skin disease often carry significant treatment limitations, resulting in poor outcomes. Poor outcomes often have a negative impact on patient quality of life, said Kim A. Papp, MD, PhD, of Probity Medical Research and K. Papp Clinical Research Inc., and lead author of the publication. Roflumilast once-daily cream demonstrated significant improvements in psoriasis signs and symptoms. Notably, roflumilast cream demonstrated favorable tolerability, without any patient discontinuation due to adverse events. The positive results from this study are encouraging for patients and clinicians who are desperate for a new topical treatment solution that will simplify disease management and improve the patient experience. Enabling patients with more effective chronic treatment in all areas of the body is our hope.

Roflumilast cream (ARQ-151) is a once-daily, highly potent, selective phosphodiesterase-4 (PDE-4) inhibitor being developed for chronic plaque psoriasis. Arcutis is currently conducting a Phase 3 clinical program with topical roflumilast cream, including two ongoing pivotal Phase 3 clinical trials (DERMIS-1 and -2). The company anticipates topline data from the Phase 3 studies in the first half of 2021.

The Phase 1/2a study assessed the safety and efficacy of once-daily roflumilast cream 0.5% and 0.15% in patients with chronic plaque psoriasis. The study enrolled a single-dose, open-label Phase 1 cohort (0.5% cream applied to 25 cm2 psoriatic plaques), and a 28-day, double-blinded Phase 2a cohort (1:1:1 randomization to roflumilast cream 0.5%, 0.15%, or vehicle). Patients had chronic plaque psoriasis of > 6 months duration with 5% body surface area involvement. Outcomes included safety (adverse events) and efficacy (percentage change in the product of Target Plaque Severity Score [TPSS] and Target Plaque Area [TPA]) at week 4.

For Cohorts 1 (n=8) and 2 (n=89), adverse events (all mild/moderate; none serious or severe) were similar between active arms and vehicle. Treatment-related events were confined to the application site, with no difference between active and vehicle. No patient discontinued treatment due to adverse events. The primary efficacy endpoint was met for both roflumilast cream doses: TPSSTPA improvement at week 4 was statistically significant for roflumilast 0.5% (P=0.0007) and 0.15% (P=0.0011) versus vehicle; significance was reached as early as 2 weeks. For both roflumilast cream doses, 66% to 67% improvement from baseline was observed at week 4, without reaching a plateau, versus 38% improvement for vehicle.

The results from this Phase 1/2a study provide further evidence of the potential of roflumilast cream as a once-daily treatment for patients with plaque psoriasis who currently lack suitable treatment options, and who often have to settle for trade-offs in drug efficacy, safety, and tolerability, said Frank Watanabe, Arcutis President and Chief Executive Officer. We believe that topical roflumilast has the potential to deliver the efficacy that enables meaningful symptomatic improvement and a safety and tolerability profile that supports chronic use and the ability to use in all body areas.

Please refer to the paper, Roflumilast Cream Improves Signs and Symptoms of Plaque Psoriasis: Results from a Phase 1/2a Randomized, Controlled Study for the full description of the design and results of this study.

About ARQ-151 (Topical Roflumilast Cream)Topical roflumilast cream is a once-daily, topical cream formulation containing roflumilast, a PDE4 inhibitor, that Arcutis is developing to treat plaque psoriasis, including intertriginous psoriasis, and atopic dermatitis. PDE4 is an intracellular enzyme that regulates pro-inflammatory and anti-inflammatory cytokine production and cell proliferation. Roflumilast was approved by the FDA for systemic treatment to reduce risk of exacerbation of chronic obstructive pulmonary disease (COPD) in 2011, has shown greater potency (25 - 300 fold) than other two FDA-approved PDE4 inhibitors used in dermatology.

About PsoriasisPsoriasis is an immune disease that occurs in about two percent of adults in western countries. About 90% of psoriasis cases is plaque psoriasis, which is characterized by plaques, or raised, red areas of skin covered with a silver or white layer of scale. Psoriatic plaques can appear on any area of the body, but most often appear on the scalp, knees, elbows, trunk, and limbs, and the plaques are often itchy and sometimes painful. Plaques in certain anatomical areas present particular treatment challenges, including the face, elbows and knees, scalp, and intertriginous areas (where two skin areas may touch or rub together).

About Arcutis - Bioscience, applied to the skin.Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. Arcutis robust pipeline includes four novel drug candidates currently in development for a range of inflammatory dermatological conditions. The companys lead product candidate, topical roflumilast, has the potential to revitalize the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis. For more information, visit https://www.arcutis.com or follow the company on LinkedIn and Twitter.

Contacts:Investor Relations:Heather Rowe ArmstrongVice President, Investor Relations & Corporate Communicationsharmstrong@arcutis.com805-418-5006, Ext. 740

View post:

The Journal of Drugs in Dermatology Publishes Results from Positive Phase 1/2a Trial of Arcutis' ARQ-151 (Topical Roflumilast Cream) for the Treatment...

For the eight million Americans living with psoriasis, the mental impact can be as great as the physical one. A dermatologist and psychologist weigh in on why treatment must address both burdens.

This story originally appeared in the August 2020 issue of Allure. Learn how tosubscribe here.

By Joel Gelfand, a professor of dermatology and epidemiology at the University of Pennsylvania Perelman School of Medicine and director of the schools Psoriasis and Phototherapy Treatment Center.

I worked on a survey that found 30-40 percent of people in the United States think psoriasis is contagious they dont want to shake the hand of someone with psoriasis. Think about that. If one in every three people that you run into on the street is going to have that view of your skin, thats a really challenging thing to cope with. Psoriasis can be socially isolating and cause people to feel anxious and depressed.

Psoriasis is not contagious. Its a common autoimmune disease of the skin, in which your body recognizes a normal skin protein as abnormal and tries to get rid of it by making skin flake off. This results in large, thick, scaly plaques that crack and bleed, and can be painful and itchy. The areas it impacts can vary, but some of the most sensitive are the scalp, face, genitals, and fingernails. A lot of patients wont wear short sleeves or shorts because their knees or elbows are affected. The typical onset is in young adulthood, but Ive seen it in infants all the way up to a patient in her 80s, who experienced it for the first time after her sister died. Studies have shown that people facing major life events are at higher risk of developing psoriasis, and that patients with psoriasis report higher levels of stress. Theres a cyclical relationship.

As tough a disease as psoriasis is, we do have a variety of ways of treating it. It can take weeks or months to see results. When the disease is localized, people like topical medications, which decrease the growth of excess skin cells [that make up psoriasis plaques]. But they may not work for some patients, and theyre inconvenient, especially if a lot of areas are affected. Pills can reduce the overactive immune response, but some can prompt gastrointestinal symptoms. Injectable medications, called biologics, are highly effective but expensive, and can make people slightly more prone to infection because they decrease immune activity in the body. My lab is researching at-home UV phototherapy, which would be more widely available than office-based ones.

Visit link:

Treating the Mental and Physical Symptoms of Psoriasis - Allure

Psoriasis impacts millions of people worldwide. It is a skin condition that causes cells to build up on the skins surface, leading to the appearance of itchy and dry, and painful red patches.While there is no strong evidence linking diet to psoriasis flare-ups, many sufferers reported worsening of their symptoms after eating certain foods and drinks. A review of 55 studies that included more than 4,500 people living with psoriasis recommended limiting caloric intake if youre overweight or obese and have the skin condition. Some psoriasis patients may be sensitive to gluten a protein found in grains including rye, barley and wheat. Researchers in Europe found that psoriasis symptoms in these people improved after they removed gluten from their diet. However, its still unclear if gluten-free diets can help all psoriasis patients. Substances in spices and condiments like pimento, curry, cinnamon, vinegar, paprika, Tabasco, Worcestershire sauce and ketchup may also cause inflammation. Some psoriasis patients have reported worsening of their symptoms after consuming these spices and condiments. Below are some other foods and drinks that you may consider cutting out to improve your psoriasis symptoms. But always discuss with your physician before making any dietary changes.

Read more:

Avoid these foods and drinks if you have psoriasis - TheHealthSite

The global Psoriasis market focuses on encompassing major statistical evidence for the Psoriasis industry as it offers our readers a value addition on guiding them in encountering the obstacles surrounding the market. A comprehensive addition of several factors such as global distribution, manufacturers, market size, and market factors that affect the global contributions are reported in the study. In addition the Psoriasis study also shifts its attention with an in-depth competitive landscape, defined growth opportunities, market share coupled with product type and applications, key companies responsible for the production, and utilized strategies are also marked.

This intelligence and 2026 forecasts Psoriasis industry report further exhibits a pattern of analyzing previous data sources gathered from reliable sources and sets a precedented growth trajectory for the Psoriasis market. The report also focuses on a comprehensive market revenue streams along with growth patterns, analytics focused on market trends, and the overall volume of the market.

Moreover, the Psoriasis report describes the market division based on various parameters and attributes that are based on geographical distribution, product types, applications, etc. The market segmentation clarifies further regional distribution for the Psoriasis market, business trends, potential revenue sources, and upcoming market opportunities.

Download PDF Sample of Psoriasis Market report @ https://hongchunresearch.com/request-a-sample/40648

Key players in the global Psoriasis market covered in Chapter 4:, Celgene Corporation, Takeda Pharmaceutical Company Limited, Pfizer Inc., Stiefel Laboratories Inc., Amgen Inc., Biogen Idec, Novartis AG, Eli Lilly and Company, Johnson and Johnson (Janssen Biotech Inc.), AbbVie Inc.

In Chapter 11 and 13.3, on the basis of types, the Psoriasis market from 2015 to 2026 is primarily split into:, Systemic, Phototherapy, Topical Treatment, Others

In Chapter 12 and 13.4, on the basis of applications, the Psoriasis market from 2015 to 2026 covers:, Injectable, Tropical, Oral

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:, North America (Covered in Chapter 6 and 13), United States, Canada, Mexico, Europe (Covered in Chapter 7 and 13), Germany, UK, France, Italy, Spain, Russia, Others, Asia-Pacific (Covered in Chapter 8 and 13), China, Japan, South Korea, Australia, India, Southeast Asia, Others, Middle East and Africa (Covered in Chapter 9 and 13), Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Others, South America (Covered in Chapter 10 and 13), Brazil, Argentina, Columbia, Chile, Others

The Psoriasis market study further highlights the segmentation of the Psoriasis industry on a global distribution. The report focuses on regions of North America, Europe, Asia, and the Rest of the World in terms of developing business trends, preferred market channels, investment feasibility, long term investments, and environmental analysis. The Psoriasis report also calls attention to investigate product capacity, product price, profit streams, supply to demand ratio, production and market growth rate, and a projected growth forecast.

In addition, the Psoriasis market study also covers several factors such as market status, key market trends, growth forecast, and growth opportunities. Furthermore, we analyze the challenges faced by the Psoriasis market in terms of global and regional basis. The study also encompasses a number of opportunities and emerging trends which are considered by considering their impact on the global scale in acquiring a majority of the market share.

The study encompasses a variety of analytical resources such as SWOT analysis and Porters Five Forces analysis coupled with primary and secondary research methodologies. It covers all the bases surrounding the Psoriasis industry as it explores the competitive nature of the market complete with a regional analysis.

Brief about Psoriasis Market Report with [emailprotected] https://hongchunresearch.com/report/psoriasis-market-40648

Some Point of Table of Content:

Chapter One: Report Overview

Chapter Two: Global Market Growth Trends

Chapter Three: Value Chain of Psoriasis Market

Chapter Four: Players Profiles

Chapter Five: Global Psoriasis Market Analysis by Regions

Chapter Six: North America Psoriasis Market Analysis by Countries

Chapter Seven: Europe Psoriasis Market Analysis by Countries

Chapter Eight: Asia-Pacific Psoriasis Market Analysis by Countries

Chapter Nine: Middle East and Africa Psoriasis Market Analysis by Countries

Chapter Ten: South America Psoriasis Market Analysis by Countries

Chapter Eleven: Global Psoriasis Market Segment by Types

Chapter Twelve: Global Psoriasis Market Segment by Applications12.1 Global Psoriasis Sales, Revenue and Market Share by Applications (2015-2020)12.1.1 Global Psoriasis Sales and Market Share by Applications (2015-2020)12.1.2 Global Psoriasis Revenue and Market Share by Applications (2015-2020)12.2 Injectable Sales, Revenue and Growth Rate (2015-2020)12.3 Tropical Sales, Revenue and Growth Rate (2015-2020)12.4 Oral Sales, Revenue and Growth Rate (2015-2020)

Chapter Thirteen: Psoriasis Market Forecast by Regions (2020-2026) continued

Check [emailprotected] https://hongchunresearch.com/check-discount/40648

List of tablesList of Tables and FiguresTable Global Psoriasis Market Size Growth Rate by Type (2020-2026)Figure Global Psoriasis Market Share by Type in 2019 & 2026Figure Systemic FeaturesFigure Phototherapy FeaturesFigure Topical Treatment FeaturesFigure Others FeaturesTable Global Psoriasis Market Size Growth by Application (2020-2026)Figure Global Psoriasis Market Share by Application in 2019 & 2026Figure Injectable DescriptionFigure Tropical DescriptionFigure Oral DescriptionFigure Global COVID-19 Status OverviewTable Influence of COVID-19 Outbreak on Psoriasis Industry DevelopmentTable SWOT AnalysisFigure Porters Five Forces AnalysisFigure Global Psoriasis Market Size and Growth Rate 2015-2026Table Industry NewsTable Industry PoliciesFigure Value Chain Status of PsoriasisFigure Production Process of PsoriasisFigure Manufacturing Cost Structure of PsoriasisFigure Major Company Analysis (by Business Distribution Base, by Product Type)Table Downstream Major Customer Analysis (by Region)Table Celgene Corporation ProfileTable Celgene Corporation Production, Value, Price, Gross Margin 2015-2020Table Takeda Pharmaceutical Company Limited ProfileTable Takeda Pharmaceutical Company Limited Production, Value, Price, Gross Margin 2015-2020Table Pfizer Inc. ProfileTable Pfizer Inc. Production, Value, Price, Gross Margin 2015-2020Table Stiefel Laboratories Inc. ProfileTable Stiefel Laboratories Inc. Production, Value, Price, Gross Margin 2015-2020Table Amgen Inc. ProfileTable Amgen Inc. Production, Value, Price, Gross Margin 2015-2020Table Biogen Idec ProfileTable Biogen Idec Production, Value, Price, Gross Margin 2015-2020Table Novartis AG ProfileTable Novartis AG Production, Value, Price, Gross Margin 2015-2020Table Eli Lilly and Company ProfileTable Eli Lilly and Company Production, Value, Price, Gross Margin 2015-2020Table Johnson and Johnson (Janssen Biotech Inc.) ProfileTable Johnson and Johnson (Janssen Biotech Inc.) Production, Value, Price, Gross Margin 2015-2020Table AbbVie Inc. ProfileTable AbbVie Inc. Production, Value, Price, Gross Margin 2015-2020Figure Global Psoriasis Sales and Growth Rate (2015-2020)Figure Global Psoriasis Revenue ($) and Growth (2015-2020)Table Global Psoriasis Sales by Regions (2015-2020)Table Global Psoriasis Sales Market Share by Regions (2015-2020)Table Global Psoriasis Revenue ($) by Regions (2015-2020)Table Global Psoriasis Revenue Market Share by Regions (2015-2020)Table Global Psoriasis Revenue Market Share by Regions in 2015Table Global Psoriasis Revenue Market Share by Regions in 2019Figure North America Psoriasis Sales and Growth Rate (2015-2020)Figure Europe Psoriasis Sales and Growth Rate (2015-2020)Figure Asia-Pacific Psoriasis Sales and Growth Rate (2015-2020)Figure Middle East and Africa Psoriasis Sales and Growth Rate (2015-2020)Figure South America Psoriasis Sales and Growth Rate (2015-2020)Figure North America Psoriasis Revenue ($) and Growth (2015-2020)Table North America Psoriasis Sales by Countries (2015-2020)Table North America Psoriasis Sales Market Share by Countries (2015-2020)Figure North America Psoriasis Sales Market Share by Countries in 2015Figure North America Psoriasis Sales Market Share by Countries in 2019Table North America Psoriasis Revenue ($) by Countries (2015-2020)Table North America Psoriasis Revenue Market Share by Countries (2015-2020)Figure North America Psoriasis Revenue Market Share by Countries in 2015Figure North America Psoriasis Revenue Market Share by Countries in 2019Figure United States Psoriasis Sales and Growth Rate (2015-2020)Figure Canada Psoriasis Sales and Growth Rate (2015-2020)Figure Mexico Psoriasis Sales and Growth (2015-2020)Figure Europe Psoriasis Revenue ($) Growth (2015-2020)Table Europe Psoriasis Sales by Countries (2015-2020)Table Europe Psoriasis Sales Market Share by Countries (2015-2020)Figure Europe Psoriasis Sales Market Share by Countries in 2015Figure Europe Psoriasis Sales Market Share by Countries in 2019Table Europe Psoriasis Revenue ($) by Countries (2015-2020)Table Europe Psoriasis Revenue Market Share by Countries (2015-2020)Figure Europe Psoriasis Revenue Market Share by Countries in 2015Figure Europe Psoriasis Revenue Market Share by Countries in 2019Figure Germany Psoriasis Sales and Growth Rate (2015-2020)Figure UK Psoriasis Sales and Growth Rate (2015-2020)Figure France Psoriasis Sales and Growth Rate (2015-2020)Figure Italy Psoriasis Sales and Growth Rate (2015-2020)Figure Spain Psoriasis Sales and Growth Rate (2015-2020)Figure Russia Psoriasis Sales and Growth Rate (2015-2020)Figure Asia-Pacific Psoriasis Revenue ($) and Growth (2015-2020)Table Asia-Pacific Psoriasis Sales by Countries (2015-2020)Table Asia-Pacific Psoriasis Sales Market Share by Countries (2015-2020)Figure Asia-Pacific Psoriasis Sales Market Share by Countries in 2015Figure Asia-Pacific Psoriasis Sales Market Share by Countries in 2019Table Asia-Pacific Psoriasis Revenue ($) by Countries (2015-2020)Table Asia-Pacific Psoriasis Revenue Market Share by Countries (2015-2020)Figure Asia-Pacific Psoriasis Revenue Market Share by Countries in 2015Figure Asia-Pacific Psoriasis Revenue Market Share by Countries in 2019Figure China Psoriasis Sales and Growth Rate (2015-2020)Figure Japan Psoriasis Sales and Growth Rate (2015-2020)Figure South Korea Psoriasis Sales and Growth Rate (2015-2020)Figure Australia Psoriasis Sales and Growth Rate (2015-2020)Figure India Psoriasis Sales and Growth Rate (2015-2020)Figure Southeast Asia Psoriasis Sales and Growth Rate (2015-2020)Figure Middle East and Africa Psoriasis Revenue ($) and Growth (2015-2020) continued

About HongChun Research:HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details:Jennifer GrayManager Global Sales+ 852 8170 0792[emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

Continue reading here:

Psoriasis Market 2020 Research Report Insights and Analysis, Forecast to 2026 - Owned

Psoriasis is an autoimmune condition that causes the immune system to over-produce skin cells. For people suffering from this condition, thick, red, scaly, itchy plaques are a common occurrence. This condition can take a toll on a persons overall quality of life. According to researchers of the Psoriasis Research Unit at Baylor Research Institute in Dallas, there is a need for psoriasis to be viewed as a serious disease affecting the whole body with significant quality of life issues. They say that, in the past, psoriasis was viewed primarily as a cosmetic nuisance that was not thought to extend beyond the obvious plaques apparent on the skin. But with the discovery of multiple genes related to this condition, a better understanding of the immune system responses involved in this disease, and the frequent associations with other serious diseases, it is now clear that psoriasis is a much more complex disease that demands continual monitoring and evaluation by a dermatologist. Also Read - Avoid these foods and drinks if you have psoriasis

This is a debilitating condition, no doubt. But you can deal with the symptoms on your own with a few home remedies. Also Read - 5 effective home remedies to treat psoriasis

This is one of the best natural remedies against psoriasis inflammation. Many experts have conducted research on this subject. Scientists say that application of aloe vera gel can reduce the redness and scaling that comes with psoriasis. You can buy this gel from the market or you can take a fresh aloe vera leaf and take out the get. Just slice the leave and scrap the gel off. Apply this to the affected area daily. Also Read - People with psoriasis can also get joint disease: The connection explained

This can help you get relief from scalp itch, which is so common in people suffering from psoriasis. Go for the organic variety and apply it to your scalp daily. You may dilute the apple cider vinegar with a little water in case it stings. But if your scalp is cracked or bleeding, avoid this treatment as it can make matters worse.

Capsaicin is a substance present in chili peppers. This gives chillies their favour and makes them spicy. If you add this to ointments, it can block nerve endings that transmit pain. It can also help reduce inflammation, redness and scaling. But be careful. It can burn people who have sensitive skin. It is best to consult a doctor before using this.

This can help you get rid of scales and reduce the itching that comes with psoriasis. Just add some to warm water and soaking in it for 15 minutes or so. But sometimes, this can cause dry skin. So be sure to apply a moisturizer after your bath.

This has antiseptic properties that can heal skin related issues. You can use a shampoo that contains tea tree oil to get relief from scalp psoriasis. You can also add a few drops to your bath water. But do an allergic test first. Some people are sensitive to this oil.

This spice has potent anti-inflammatory and antioxidant properties. Curcumin in turmeric is known to alter gene expression. This can reduce flare-ups. Just add it to your daily food. You can also have a one-inch piece of raw turmeric every morning.

Published : July 30, 2020 5:03 pm | Updated:July 31, 2020 10:14 am

Read the original post:

Turmeric, apple cider vinegar and other home remedies for psoriasis - TheHealthSite

Evaluation of the Global Plaque Psoriasis Treatment Market

The presented study maps the growth trajectory of the global Plaque Psoriasis Treatment market by thoroughly assessing the various factors that are expected to influence the future prospects of the Plaque Psoriasis Treatment market. According to the report published by PMR, the Plaque Psoriasis Treatment market is poised to attain a value of ~US$ XX Mn/Bn by the end of 2029 with a CAGR growth of ~XX% during the forecast period (2019-2029).

A complete evaluation of the trends, market drivers, opportunities, and challenges faced by market players operating in the Plaque Psoriasis Treatment market is provided in the report. Further, an overview and introduction of the Plaque Psoriasis Treatment market is included to ensure that the readers have a seamless experience while going through the contents of the report.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/16069

Critical insights included in the report:

Competitive Outlook

The competitive outlook assessment provides an in-depth understanding related to the business proceeding of top-tier market players in the global Plaque Psoriasis Treatment market. The product portfolio, sales strategy, marketing & promotional strategy, and sales footprint of each market player is scrutinized thoroughly in the report. Some of the leading players evaluated in the report include:

The report segments the global Plaque Psoriasis Treatment market on the basis of region, product type, and end use.

market players are also exploring the developing market. Novartis launched its Cosentyx in Japan for the treatment of psoriasis arthritis in adults who are not adequately responding to systemic therapy.

Plaque Psoriasis Treatment Market: Market Players

Company manufacturer is converting innovative research into a new therapy by constantly investing in research activities. The number of drugs approved for plaque psoriasis is constantly increasing the number of treatment options for the physician and patients. Eli Lillys interleukin inhibitor was approved by the FDA, second molecule to be approved after Novartis Cosentyx.

Some of the plaque psoriasis treatment market contributors are Allergan, Johnson and Johnson, Amgen, Abbvie, Eli Lilly, Dermira Inc., Novartis, Galectin Therapeutics, Cellceutix Corporation and Biogen Inc., Bayer.

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/16069

Regional Analysis

The market scenario in each region along with a comprehensive assessment of the micro and macro-economic factors that are forecasted to impact the market growth in these regions is included in the report.

End Use Assessment

The market study offers accurate and in-depth analysis of the various end uses of the Plaque Psoriasis Treatment along with a yearly comparison of the market share and revenue growth of each end use.

Important queries addressed in the report:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/16069

Why Opt for PMR?

See the rest here:

Plaque Psoriasis Treatment Market Slated to Grow at an Impressive CAGR of XX% During the Forecast Period 2017 - 2025 - Market Research Correspondent

Global Psoriasis Treatment Market was valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of 9.3 % during forecast period of 2019 to 2026.

REQUEST FOR FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/request-sample/37175

Psoriasis is a long-lasting autoimmune disease characterized by patches of abnormal skin growth, skin patches are typically red, dry, itchy, and scaly.

Global Psoriasis Treatment Market Drivers and Restrain

Rising prevalence of the condition, heading with growing awareness, the screening and diagnosis of the disease are expected to fuel the global psoriasis treatment market in the coming years. Psoriasis treatment options also contribute to a number of side-effects such as liver and kidney damage, hypertension, and increased risk of cancer, etc., are the factors could hamper the growth of Global Psoriasis Treatment Market in forecast period.

Global Psoriasis Treatment Market key segmentation

By drug class, the global market has been categorized into TNF inhibitors, Interleukin inhibitors, Vitamin D analogs, Corticosteroids, and others. Tumour Necrosis Factor Inhibitors is further categorized as Adalimumab, Infliximab, Etanercept. Vitamin D Analogues is segmented into Calcitriol, Calcipotriol, Tacalcitol. The Interleukin inhibitors segment is projected to lead the global psoriasis treatment market during the forecast period.

High market share of the interleukin inhibitors segment can be attributed to the superior efficacy and safety of drugs in this class for the treatment of psoriasis. Moreover, the acceptance of this drug class is attributable to interleukin blockers, which are considered to be a viable option for patients having trouble responding to other treatment.

Global Psoriasis Treatment Market Regional Analysis

By region, the global psoriasis market to witness dominance of North America followed by Europe. As per the National Psoriasis Foundation, there are about X million people in America living with psoriasis. Because of quick adoption of biological therapy and rise in investments on research and development for clinical trials will drive global market in this region. On the other side, the emerging markets in the Middle East and Africa, Latin America, and Asia Pacific are expected to offer growth opportunities thanks to increasing patient pool, the improving healthcare infrastructure and medical facilities.

The objective of the report is to present comprehensive analysis of Global Psoriasis Treatment Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language.

DO INQUIRY BEFORE PURCHASING REPORT HERE: https://www.maximizemarketresearch.com/inquiry-before-buying/37175

The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.

The report also helps in understanding Global Psoriasis Treatment Market dynamics, structure by analyzing the market segments, and project the Global Psoriasis Treatment Market size. Clear representation of competitive analysis of key players by Psoriasis Treatment Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Psoriasis Treatment Market.Scope of the Global Psoriasis Treatment Market

Global Psoriasis Treatment Market Drug class

Corticosteroids Tumour Necrosis Factor Inhibitors interleukin inhibitors Vitamin D AnaloguesGlobal Psoriasis Treatment Market by Treatment

Biologic Drugs Small Molecule Systemic Drugs Tropical TherapiesGlobal Psoriasis Treatment Market by Route of administration

Oral Parenteral TopicalGlobal Psoriasis Treatment Market by region

North America Europe Asia Pacific Middle East & Africa South AmericaKey players operating on Global Psoriasis Treatment Market

AbbVie Inc., Amgen Inc., AstraZeneca, Biogen, Boehringer Ingelheim, Celgene, Eli Lilly and Company, Johnson & Johnson, LEO Pharma A/S, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Stiefel Laboratories Inc. (GlaxoSmithKline plc.), Sun Pharmaceutical Industries

MAJOR TOC OF THE REPORT

Chapter One: Psoriasis Treatment Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Psoriasis Treatment Market Competition, by Players

Chapter Four: Global Psoriasis Treatment Market Size by Regions

Chapter Five: North America Psoriasis Treatment Revenue by Countries

Chapter Six: Europe Psoriasis Treatment Revenue by Countries

Chapter Seven: Asia-Pacific Psoriasis Treatment Revenue by Countries

Chapter Eight: South America Psoriasis Treatment Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Psoriasis Treatment by Countries

Chapter Ten: Global Psoriasis Treatment Market Segment by Type

Chapter Eleven: Global Psoriasis Treatment Market Segment by Application

Chapter Twelve: Global Psoriasis Treatment Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Psoriasis Treatment Market Report at: https://www.maximizemarketresearch.com/market-report/global-psoriasis-treatment-market/37175/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Read the rest here:

Global Psoriasis Treatment Market Industry Analysis and forecast (2019 to 2026) By treatment, technology, End-use and Region - WOLE TV

Psoriasis is a common disease, and more than eight million Americans have it, according to the National Psoriasis Foundation.

Psoriasis comes and goes in spurts. When the disease is active, it is called a flare. Flares can last for weeks or months and then go into remission or subside. Manifestations of the disease range from a few spots of scaly skin that resemble dandruff to more severe flare-ups that cover bigger areas of the body.

Its not contagious, but its more than a cosmetic problem. About 60 percent of people with psoriasis said the disease interferes with their daily lives.

There is no cure for psoriasis, but people with psoriasis have treatment options aimed at controlling symptoms. Common treatments include light therapy (phototherapy), ointments, and medications.

Expand

Psoriasis signs and symptoms vary from person to person. Depending on the type and severity of the disease, it may manifest differently.

People with psoriasis are also more likely to have co-occurring health conditions, including cardiovascular problems, obesity, high blood pressure and diabetes.

Common signs and symptoms include:

Psoriasis can be mild, moderate or severe depending on the percent of body surface area affected. The scale goes from less than three percent to over 10 percent.

For reference, a hand is about the same as one percent of skin surface, according to The National Psoriasis Foundation. How a persons quality of life is affected is also a factor in classifying disease severity.

Expand

Scientists dont know exactly what causes psoriasis, but they know its an autoimmune disease. This means the bodys immune system overreacts, causing other health problems.

Immune cells called T cells become overactive and trigger immune responses such as swelling and abnormally quick skin cell growth, according to the National Institute of Arthritis and Musculoskeletal and Skin Diseases.

In people without psoriasis, skin cells usually take about a month to go through their life cycle. But in people with psoriasis, it only takes a few days. These extra skin cells grow deep in the skin and rise to the surface, causing red, scaly patches.

A few factors can cause flares.

Some things that trigger symptoms or flares include:

Research suggests that psoriasis is hereditary, meaning it runs in families. One in three people with psoriasis report having a family member with the disease.

A child with one parent with psoriasis has a 10 percent chance of also having it. If a child has two parents with psoriasis, the likelihood they will get the disease increases to 50 percent, according to the National Psoriasis Foundation.

Most of these types of disease are chronic, but not life threatening. The rarest type, called erythrodermic psoriasis, is a severe disease and is a medical emergency.

According to the National Psoriasis Foundation, there are five main types of psoriasis. Each type differs in severity and symptoms. Doctors will vary the treatment recommendations depending on the type.

Plaque psoriasis is the most common form. It appears as patches of red, raised skin covered with a silvery buildup of dead skin. These patches most commonly affect the scalp, elbows, knees and lower back.

Guttate psoriasis most often affects children or young adults. This type of psoriasis appears as small, red, scaly dots on the trunk, arms and legs. Strep throat infections are a typical trigger.

Inverse psoriasis affects the body in places with skin folds such as behind the knee, in the groin or under the arm. Unlike plaque psoriasis, it typically appears red, shiny and smooth. People who have this type of psoriasis usually have it on more than one part of the body at the same time.

Pustular psoriasis is a rarer type of psoriasis that manifests as red skin with pustules, or blisters, filled with non-infectious pus. It occurs most often on the hands or feet, though it can occur anywhere on the body. The liquid in the blisters is made of white blood cells, and despite how it looks it is not an infection nor is it contagious.

Erythrodermic psoriasis is a very severe, but rare form of the disease. Only about three percent of people with psoriasis have this type. It causes extreme, widespread redness over most of the body. Skin layers come off in sheets and cause severe itching and pain. It can also cause dehydration, body temperature changes, changes in heart rate and nail changes.

This is a medical emergency. Seek medical help right away if you think you have erythrodermic psoriasis because it can be life threatening.

Doctors diagnose psoriasis by examining the rash or lesions. He or she will look at the scales and plaques and where they appear on the body.

Sometimes, the doctor will take a skin sample and send it off to a lab, a procedure called a biopsy. This allows the doctor to rule out other skin disorders such as skin cancer.

Treatment for psoriasis includes topical therapy, phototherapy (light therapy) and medications. Sometimes, doctors may recommend a combination of treatments.

Topical therapies typically come in the form of creams, shampoos, lotions, gels or ointments applied directly to the skin.

Examples of topical therapy include:

Phototherapy is the go-to treatment for moderate to severe psoriasis. The doctor may recommend it alone or with medications. This type of therapy exposes the skin to controlled amounts of artificial or natural light to control psoriasis.

The light source may be natural sunlight, also called heliotherapy. Artificial light techniques include UVB broadband and narrowband therapy, Psoralen plus ultraviolet A and targeted laser therapy.

Side effects include skin dryness, itchy skin, skin burns, freckles, increased sun sensitivity and increased skin cancer risk. Moisturizing regularly may help with itchiness and dryness.

Medications for psoriasis include immunosuppressants and biologic agents that suppress the immune system to prevent psoriasis symptoms. These drugs reduce the bodys ability to fight off infections and may cause damage to organs such as the liver and kidneys.

Medications for psoriasis include:

Psoriasis and eczema both cause itchy, red skin and it can be difficult to tell these rashes apart. The biggest difference is that psoriasis is an autoimmune disorder, and eczema is not.

Psoriasis tends to have a milder itchiness, whereas eczema can be more intense. The places most commonly affected by psoriasis are the scalp, elbows, knees, buttocks and face. Eczema most often occurs on the inside of the elbows or the back of the knees.

The rash caused by eczema usually comes with fluid leaking through the skin, whereas psoriasis is a thicker plaque with dry scaling.

The best way to tell these two rashes apart is to see a dermatologist.

Read more:

Psoriasis | Symptoms, Causes, Types and Treatments - DrugWatch.com

LOS ANGELES, United States: QY Research has recently published a report, titled Global Psoriasis Treatment Market Research Report 2020. The research report gives the potential headway openings that prevails in the global market. The report is amalgamated depending on research procured from primary and secondary information. The global Psoriasis Treatment market is relied upon to develop generously and succeed in volume and value during the predicted time period. Moreover, the report gives nitty gritty data on different manufacturers, region, and products which are important to totally understanding the market.

Key Companies/Manufacturers operating in the global Psoriasis Treatment market include: , Novartis International AG, Johnson & Johnson, Pfizer Inc., Merck and Co. Inc., AbbVie and Amgen, Eli Lilly,

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/2008650/global-psoriasis-treatment-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Psoriasis Treatment market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Psoriasis Treatment Market Segment By Type:

TNF InhibitorsPhosphodiesterase InhibitorsInterleukin BlockersOthers

Global Psoriasis Treatment Market Segment By Application:

OralInjectable

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Psoriasis Treatment market.

Key companies operating in the global Psoriasis Treatment market include , Novartis International AG, Johnson & Johnson, Pfizer Inc., Merck and Co. Inc., AbbVie and Amgen, Eli Lilly,

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/2008650/global-psoriasis-treatment-market

TOC

1 Psoriasis Treatment Market Overview1.1 Product Overview and Scope of Psoriasis Treatment1.2 Psoriasis Treatment Segment by Type1.2.1 Global Psoriasis Treatment Sales Growth Rate Comparison by Type (2021-2026)1.2.2 TNF Inhibitors1.2.3 Phosphodiesterase Inhibitors1.2.4 Interleukin Blockers1.2.5 Others1.3 Psoriasis Treatment Segment by Application1.3.1 Psoriasis Treatment Sales Comparison by Application: 2020 VS 20261.3.2 Oral1.3.3 Injectable1.4 Global Psoriasis Treatment Market Size Estimates and Forecasts1.4.1 Global Psoriasis Treatment Revenue 2015-20261.4.2 Global Psoriasis Treatment Sales 2015-20261.4.3 Psoriasis Treatment Market Size by Region: 2020 Versus 20261.5 Psoriasis Treatment Industry1.6 Psoriasis Treatment Market Trends 2 Global Psoriasis Treatment Market Competition by Manufacturers2.1 Global Psoriasis Treatment Sales Market Share by Manufacturers (2015-2020)2.2 Global Psoriasis Treatment Revenue Share by Manufacturers (2015-2020)2.3 Global Psoriasis Treatment Average Price by Manufacturers (2015-2020)2.4 Manufacturers Psoriasis Treatment Manufacturing Sites, Area Served, Product Type2.5 Psoriasis Treatment Market Competitive Situation and Trends2.5.1 Psoriasis Treatment Market Concentration Rate2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)2.6 Manufacturers Mergers & Acquisitions, Expansion Plans2.7 Primary Interviews with Key Psoriasis Treatment Players (Opinion Leaders) 3 Psoriasis Treatment Retrospective Market Scenario by Region3.1 Global Psoriasis Treatment Retrospective Market Scenario in Sales by Region: 2015-20203.2 Global Psoriasis Treatment Retrospective Market Scenario in Revenue by Region: 2015-20203.3 North America Psoriasis Treatment Market Facts & Figures by Country3.3.1 North America Psoriasis Treatment Sales by Country3.3.2 North America Psoriasis Treatment Sales by Country3.3.3 U.S.3.3.4 Canada3.4 Europe Psoriasis Treatment Market Facts & Figures by Country3.4.1 Europe Psoriasis Treatment Sales by Country3.4.2 Europe Psoriasis Treatment Sales by Country3.4.3 Germany3.4.4 France3.4.5 U.K.3.4.6 Italy3.4.7 Russia3.5 Asia Pacific Psoriasis Treatment Market Facts & Figures by Region3.5.1 Asia Pacific Psoriasis Treatment Sales by Region3.5.2 Asia Pacific Psoriasis Treatment Sales by Region3.5.3 China3.5.4 Japan3.5.5 South Korea3.5.6 India3.5.7 Australia3.5.8 Taiwan3.5.9 Indonesia3.5.10 Thailand3.5.11 Malaysia3.5.12 Philippines3.5.13 Vietnam3.6 Latin America Psoriasis Treatment Market Facts & Figures by Country3.6.1 Latin America Psoriasis Treatment Sales by Country3.6.2 Latin America Psoriasis Treatment Sales by Country3.6.3 Mexico3.6.3 Brazil3.6.3 Argentina3.7 Middle East and Africa Psoriasis Treatment Market Facts & Figures by Country3.7.1 Middle East and Africa Psoriasis Treatment Sales by Country3.7.2 Middle East and Africa Psoriasis Treatment Sales by Country3.7.3 Turkey3.7.4 Saudi Arabia3.7.5 U.A.E 4 Global Psoriasis Treatment Historic Market Analysis by Type4.1 Global Psoriasis Treatment Sales Market Share by Type (2015-2020)4.2 Global Psoriasis Treatment Revenue Market Share by Type (2015-2020)4.3 Global Psoriasis Treatment Price Market Share by Type (2015-2020)4.4 Global Psoriasis Treatment Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Global Psoriasis Treatment Historic Market Analysis by Application5.1 Global Psoriasis Treatment Sales Market Share by Application (2015-2020)5.2 Global Psoriasis Treatment Revenue Market Share by Application (2015-2020)5.3 Global Psoriasis Treatment Price by Application (2015-2020) 6 Company Profiles and Key Figures in Psoriasis Treatment Business6.1 Novartis International AG6.1.1 Corporation Information6.1.2 Novartis International AG Description, Business Overview and Total Revenue6.1.3 Novartis International AG Psoriasis Treatment Sales, Revenue and Gross Margin (2015-2020)6.1.4 Novartis International AG Products Offered6.1.5 Novartis International AG Recent Development6.2 Johnson & Johnson6.2.1 Johnson & Johnson Corporation Information6.2.2 Johnson & Johnson Description, Business Overview and Total Revenue6.2.3 Johnson & Johnson Psoriasis Treatment Sales, Revenue and Gross Margin (2015-2020)6.2.4 Johnson & Johnson Products Offered6.2.5 Johnson & Johnson Recent Development6.3 Pfizer Inc.6.3.1 Pfizer Inc. Corporation Information6.3.2 Pfizer Inc. Description, Business Overview and Total Revenue6.3.3 Pfizer Inc. Psoriasis Treatment Sales, Revenue and Gross Margin (2015-2020)6.3.4 Pfizer Inc. Products Offered6.3.5 Pfizer Inc. Recent Development6.4 Merck and Co. Inc.6.4.1 Merck and Co. Inc. Corporation Information6.4.2 Merck and Co. Inc. Description, Business Overview and Total Revenue6.4.3 Merck and Co. Inc. Psoriasis Treatment Sales, Revenue and Gross Margin (2015-2020)6.4.4 Merck and Co. Inc. Products Offered6.4.5 Merck and Co. Inc. Recent Development6.5 AbbVie and Amgen6.5.1 AbbVie and Amgen Corporation Information6.5.2 AbbVie and Amgen Description, Business Overview and Total Revenue6.5.3 AbbVie and Amgen Psoriasis Treatment Sales, Revenue and Gross Margin (2015-2020)6.5.4 AbbVie and Amgen Products Offered6.5.5 AbbVie and Amgen Recent Development6.6 Eli Lilly6.6.1 Eli Lilly Corporation Information6.6.2 Eli Lilly Description, Business Overview and Total Revenue6.6.3 Eli Lilly Psoriasis Treatment Sales, Revenue and Gross Margin (2015-2020)6.6.4 Eli Lilly Products Offered6.6.5 Eli Lilly Recent Development 7 Psoriasis Treatment Manufacturing Cost Analysis7.1 Psoriasis Treatment Key Raw Materials Analysis7.1.1 Key Raw Materials7.1.2 Key Raw Materials Price Trend7.1.3 Key Suppliers of Raw Materials7.2 Proportion of Manufacturing Cost Structure7.3 Manufacturing Process Analysis of Psoriasis Treatment7.4 Psoriasis Treatment Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers8.1 Marketing Channel8.2 Psoriasis Treatment Distributors List8.3 Psoriasis Treatment Customers 9 Market Dynamics9.1 Market Trends9.2 Opportunities and Drivers9.3 Challenges9.4 Porters Five Forces Analysis 10 Global Market Forecast10.1 Global Psoriasis Treatment Market Estimates and Projections by Type10.1.1 Global Forecasted Sales of Psoriasis Treatment by Type (2021-2026)10.1.2 Global Forecasted Revenue of Psoriasis Treatment by Type (2021-2026)10.2 Psoriasis Treatment Market Estimates and Projections by Application10.2.1 Global Forecasted Sales of Psoriasis Treatment by Application (2021-2026)10.2.2 Global Forecasted Revenue of Psoriasis Treatment by Application (2021-2026)10.3 Psoriasis Treatment Market Estimates and Projections by Region10.3.1 Global Forecasted Sales of Psoriasis Treatment by Region (2021-2026)10.3.2 Global Forecasted Revenue of Psoriasis Treatment by Region (2021-2026)10.4 North America Psoriasis Treatment Estimates and Projections (2021-2026)10.5 Europe Psoriasis Treatment Estimates and Projections (2021-2026)10.6 Asia Pacific Psoriasis Treatment Estimates and Projections (2021-2026)10.7 Latin America Psoriasis Treatment Estimates and Projections (2021-2026)10.8 Middle East and Africa Psoriasis Treatment Estimates and Projections (2021-2026) 11 Research Finding and Conclusion 12 Methodology and Data Source12.1 Methodology/Research Approach12.1.1 Research Programs/Design12.1.2 Market Size Estimation12.1.3 Market Breakdown and Data Triangulation12.2 Data Source12.2.1 Secondary Sources12.2.2 Primary Sources12.3 Author List12.4 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

View original post here:

Trending Now: Psoriasis Treatment Market Study for 2020 to 2026 Providing Information on Key Players, Growth Drivers and Industry Challenges| Novartis...

[July 27th 2020] - INCHEON, SOUTH KOREA Celltrion Healthcare today announced that the European Commission (EC) has granted marketing authorisation for Remsima (infliximab, CT-P13) subcutaneous (SC) formulation for the treatment of adult patients with ankylosing spondylitis, Crohns disease, ulcerative colitis, psoriatic arthritis and psoriasis.[i]

The approval follows a positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in June and is based on data from a pivotal study comparing the pharmacokinetics, efficacy and safety of the SC and intravenous (IV) formulations of Remsima in people with active Crohns disease and ulcerative colitis, throughout a 1-year treatment period.[ii],[iii] Based on the results of the pivotal study, a 120 mg fixed dose of Remsima SC has been approved for use in the European Union (EU), in adults regardless of body weight, in both existing and newly added indications.

Professor Stefan Schreiber, Director of the Clinic for Internal Medicine at Kiel Campus of the University Hospital Schleswig-Holstein in Germany said: The subcutaneous formulation of Remsima (Remsima SC) has been shown to have very high efficacy, and favourable data, which are fully comparable to the efficacy and safety profile of the IV formulation. Todays approval marks an important progress for the gastroenterology community as it means that treatment can now be administered in significantly less time, thereby providing patients more flexibility and control over how they receive their treatment.

We are pleased to announce this important regulatory milestone earlier than we expected, with the European Commission prioritising review of this important new administration option. We will accelerate the launch process on a country-by-country basis in order to expand treatment options for patients with chronic inflammatory diseases such as inflammatory bowel disease and ankylosing spondylitis, said Hyoung-Ki Kim, Vice Chairman at Celltrion Healthcare. We will do our best to make Remsima SC available as early as possible and hope this medication will contribute to minimising the risks involved with administering medical treatments during the COVID-19 pandemic.

Celltrion anticipates receiving approval of Remsima SC in 97 countries, including 31 countries in Europe.

[i] European Medicines Agency Summary of Product Characteristics (SmPC). Remsima.

[ii] Reinisch W, et al. A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year result from a Phase 1 open-label randomised controlled trial in patients with active Crohns disease. European Crohns and Colitis Organisation 2019. Abstract no: A-1103.

[iii] Ben-Horin S, et al. A novel subcutaneous infliximab (CT-P13): 1-year results including switching results from intravenous infliximab (CT-P13) in patients with active Crohns disease and ulcerative colitis. Oral presentation (OP24). Presented at ECCO 2020.

The rest is here:

European Commission grants marketing authorisation for world's first subcutaneous formulation of infliximab, Remsima SC, for an additional five indic...

QY Research has Published Latest Trending Report on Global Psoriasis Treatment Market

Los Angeles, United State, The report titledGlobal Psoriasis Treatment Marketis one of the most comprehensive and important additions to QY Researchs archive of market research studies. It offers detailed research and analysis of key aspects of the global Psoriasis Treatment market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Psoriasis Treatment market. Market participants can use the analysis on market dynamics to plan effective growth strategies and prepare for future challenges beforehand. Each trend of the global Psoriasis Treatment market is carefully analyzed and researched about by the market analysts

Market Insight

.Psoriasis is a chronic non-contagious disease in which a persons immune system sends faulty signals directing skin cells to grow too quickly. Globally North America is the largest market of global psoriasis treatment. Europe is the second largest market for global psoriasis treatment. However the developing market is Asia Pacific that will be the fastest growing region and will be the key to the future. The global Psoriasis Treatment market size is projected to reach US$ 24560 million by 2026, from US$ 15900 million in 2020, at a CAGR of 7.5% during 2021-2026

Request Sample Report and Full Report TOC:https://www.qyresearch.com/sample-form/form/2008650/global-psoriasis-treatment-market

. This report focuses on Psoriasis Treatment volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Psoriasis Treatment market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, etc. Global Psoriasis Treatment Market: Segment Analysis The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Global Psoriasis Treatment Market: Regional Analysis The research report includes a detailed study of regions of North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue, sales, and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2015 to 2026. These analyses will help the reader to understand the potential worth of investment in a particular region. Global Psoriasis Treatment Market:

Competitive Landscape

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.

Following are the segments covered by the report are:

, TNF Inhibitors, Phosphodiesterase Inhibitors, Interleukin Blockers, Others

By Application:

Oral, Injectable Key Players:

The Key manufacturers that are operating in the global Psoriasis Treatment market are: Novartis International AG, Johnson & Johnson, Pfizer Inc., Merck and Co. Inc., AbbVie and Amgen, Eli Lilly,

Competitive Landscape The analysts have provided a comprehensive analysis of the Competitive Landscape of the global Psoriasis Treatment market with the company market structure and market share analysis of the top players. The innovative trends and developments, mergers and acquisitions, product portfolio, and new product innovation to provide a dashboard view of the market, ultimately providing the readers accurate measure of the current market developments, business strategies, and key financials.

Reasons to Buy this Report:

Table of Contents

1 Psoriasis Treatment Market Overview1.1 Product Overview and Scope of Psoriasis Treatment1.2 Psoriasis Treatment Segment by Type1.2.1 Global Psoriasis Treatment Sales Growth Rate Comparison by Type (2021-2026)1.2.2 TNF Inhibitors1.2.3 Phosphodiesterase Inhibitors1.2.4 Interleukin Blockers1.2.5 Others1.3 Psoriasis Treatment Segment by Application1.3.1 Psoriasis Treatment Sales Comparison by Application: 2020 VS 20261.3.2 Oral1.3.3 Injectable1.4 Global Psoriasis Treatment Market Size Estimates and Forecasts1.4.1 Global Psoriasis Treatment Revenue 2015-20261.4.2 Global Psoriasis Treatment Sales 2015-20261.4.3 Psoriasis Treatment Market Size by Region: 2020 Versus 20261.5 Psoriasis Treatment Industry1.6 Psoriasis Treatment Market Trends 2 Global Psoriasis Treatment Market Competition by Manufacturers2.1 Global Psoriasis Treatment Sales Market Share by Manufacturers (2015-2020)2.2 Global Psoriasis Treatment Revenue Share by Manufacturers (2015-2020)2.3 Global Psoriasis Treatment Average Price by Manufacturers (2015-2020)2.4 Manufacturers Psoriasis Treatment Manufacturing Sites, Area Served, Product Type2.5 Psoriasis Treatment Market Competitive Situation and Trends2.5.1 Psoriasis Treatment Market Concentration Rate2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)2.6 Manufacturers Mergers & Acquisitions, Expansion Plans2.7 Primary Interviews with Key Psoriasis Treatment Players (Opinion Leaders) 3 Psoriasis Treatment Retrospective Market Scenario by Region3.1 Global Psoriasis Treatment Retrospective Market Scenario in Sales by Region: 2015-20203.2 Global Psoriasis Treatment Retrospective Market Scenario in Revenue by Region: 2015-20203.3 North America Psoriasis Treatment Market Facts & Figures by Country3.3.1 North America Psoriasis Treatment Sales by Country3.3.2 North America Psoriasis Treatment Sales by Country3.3.3 U.S.3.3.4 Canada3.4 Europe Psoriasis Treatment Market Facts & Figures by Country3.4.1 Europe Psoriasis Treatment Sales by Country3.4.2 Europe Psoriasis Treatment Sales by Country3.4.3 Germany3.4.4 France3.4.5 U.K.3.4.6 Italy3.4.7 Russia3.5 Asia Pacific Psoriasis Treatment Market Facts & Figures by Region3.5.1 Asia Pacific Psoriasis Treatment Sales by Region3.5.2 Asia Pacific Psoriasis Treatment Sales by Region3.5.3 China3.5.4 Japan3.5.5 South Korea3.5.6 India3.5.7 Australia3.5.8 Taiwan3.5.9 Indonesia3.5.10 Thailand3.5.11 Malaysia3.5.12 Philippines3.5.13 Vietnam3.6 Latin America Psoriasis Treatment Market Facts & Figures by Country3.6.1 Latin America Psoriasis Treatment Sales by Country3.6.2 Latin America Psoriasis Treatment Sales by Country3.6.3 Mexico3.6.3 Brazil3.6.3 Argentina3.7 Middle East and Africa Psoriasis Treatment Market Facts & Figures by Country3.7.1 Middle East and Africa Psoriasis Treatment Sales by Country3.7.2 Middle East and Africa Psoriasis Treatment Sales by Country3.7.3 Turkey3.7.4 Saudi Arabia3.7.5 U.A.E 4 Global Psoriasis Treatment Historic Market Analysis by Type4.1 Global Psoriasis Treatment Sales Market Share by Type (2015-2020)4.2 Global Psoriasis Treatment Revenue Market Share by Type (2015-2020)4.3 Global Psoriasis Treatment Price Market Share by Type (2015-2020)4.4 Global Psoriasis Treatment Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Global Psoriasis Treatment Historic Market Analysis by Application5.1 Global Psoriasis Treatment Sales Market Share by Application (2015-2020)5.2 Global Psoriasis Treatment Revenue Market Share by Application (2015-2020)5.3 Global Psoriasis Treatment Price by Application (2015-2020) 6 Company Profiles and Key Figures in Psoriasis Treatment Business6.1 Novartis International AG6.1.1 Corporation Information6.1.2 Novartis International AG Description, Business Overview and Total Revenue6.1.3 Novartis International AG Psoriasis Treatment Sales, Revenue and Gross Margin (2015-2020)6.1.4 Novartis International AG Products Offered6.1.5 Novartis International AG Recent Development6.2 Johnson & Johnson6.2.1 Johnson & Johnson Corporation Information6.2.2 Johnson & Johnson Description, Business Overview and Total Revenue6.2.3 Johnson & Johnson Psoriasis Treatment Sales, Revenue and Gross Margin (2015-2020)6.2.4 Johnson & Johnson Products Offered6.2.5 Johnson & Johnson Recent Development6.3 Pfizer Inc.6.3.1 Pfizer Inc. Corporation Information6.3.2 Pfizer Inc. Description, Business Overview and Total Revenue6.3.3 Pfizer Inc. Psoriasis Treatment Sales, Revenue and Gross Margin (2015-2020)6.3.4 Pfizer Inc. Products Offered6.3.5 Pfizer Inc. Recent Development6.4 Merck and Co. Inc.6.4.1 Merck and Co. Inc. Corporation Information6.4.2 Merck and Co. Inc. Description, Business Overview and Total Revenue6.4.3 Merck and Co. Inc. Psoriasis Treatment Sales, Revenue and Gross Margin (2015-2020)6.4.4 Merck and Co. Inc. Products Offered6.4.5 Merck and Co. Inc. Recent Development6.5 AbbVie and Amgen6.5.1 AbbVie and Amgen Corporation Information6.5.2 AbbVie and Amgen Description, Business Overview and Total Revenue6.5.3 AbbVie and Amgen Psoriasis Treatment Sales, Revenue and Gross Margin (2015-2020)6.5.4 AbbVie and Amgen Products Offered6.5.5 AbbVie and Amgen Recent Development6.6 Eli Lilly6.6.1 Eli Lilly Corporation Information6.6.2 Eli Lilly Description, Business Overview and Total Revenue6.6.3 Eli Lilly Psoriasis Treatment Sales, Revenue and Gross Margin (2015-2020)6.6.4 Eli Lilly Products Offered6.6.5 Eli Lilly Recent Development 7 Psoriasis Treatment Manufacturing Cost Analysis7.1 Psoriasis Treatment Key Raw Materials Analysis7.1.1 Key Raw Materials7.1.2 Key Raw Materials Price Trend7.1.3 Key Suppliers of Raw Materials7.2 Proportion of Manufacturing Cost Structure7.3 Manufacturing Process Analysis of Psoriasis Treatment7.4 Psoriasis Treatment Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers8.1 Marketing Channel8.2 Psoriasis Treatment Distributors List8.3 Psoriasis Treatment Customers 9 Market Dynamics9.1 Market Trends9.2 Opportunities and Drivers9.3 Challenges9.4 Porters Five Forces Analysis 10 Global Market Forecast10.1 Global Psoriasis Treatment Market Estimates and Projections by Type10.1.1 Global Forecasted Sales of Psoriasis Treatment by Type (2021-2026)10.1.2 Global Forecasted Revenue of Psoriasis Treatment by Type (2021-2026)10.2 Psoriasis Treatment Market Estimates and Projections by Application10.2.1 Global Forecasted Sales of Psoriasis Treatment by Application (2021-2026)10.2.2 Global Forecasted Revenue of Psoriasis Treatment by Application (2021-2026)10.3 Psoriasis Treatment Market Estimates and Projections by Region10.3.1 Global Forecasted Sales of Psoriasis Treatment by Region (2021-2026)10.3.2 Global Forecasted Revenue of Psoriasis Treatment by Region (2021-2026)10.4 North America Psoriasis Treatment Estimates and Projections (2021-2026)10.5 Europe Psoriasis Treatment Estimates and Projections (2021-2026)10.6 Asia Pacific Psoriasis Treatment Estimates and Projections (2021-2026)10.7 Latin America Psoriasis Treatment Estimates and Projections (2021-2026)10.8 Middle East and Africa Psoriasis Treatment Estimates and Projections (2021-2026) 11 Research Finding and Conclusion 12 Methodology and Data Source12.1 Methodology/Research Approach12.1.1 Research Programs/Design12.1.2 Market Size Estimation12.1.3 Market Breakdown and Data Triangulation12.2 Data Source12.2.1 Secondary Sources12.2.2 Primary Sources12.3 Author List12.4 Disclaimer

About US

QY Research is a leading global market research and consulting company. Established in 2007 in Beijing, China, QY Research focuses on management consulting, database and seminar services, IPO consulting, industry chain research and custom research to help our clients in providing non-linear revenue model and make them successful. We are globally recognized for our expansive portfolio of services.

Read more:

Psoriasis Treatment Market Thriving worldwide With Top Key Player| Johnson & Johnson, Pfizer Inc., Merck and Co. Inc. - Research Newspaper